Form 4: Bausch + Lomb Executive Reports Routine Share Withholding for Tax Obligations

Bausch + Lomb's EVP of R&D and CMO, Yehia Hashad, reported the withholding of 2,841 common shares valued at $14.32 per share to cover tax obligations related to restricted share unit vesting.

Summary

• Yehia Hashad, Executive Vice President of Research & Development and Chief Medical Officer of Bausch & Lomb Corp (BLCO), reported a transaction.
• On July 25, 2025, 2,841 common shares with no par value were disposed of.
• The disposition was coded 'F', indicating shares were withheld to satisfy tax withholding obligations due upon the vesting of restricted share units.
• The price per share for the withheld shares was $14.32.
• Following this transaction, Yehia Hashad beneficially owns 116,739 common shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (tax withholding on RSU vesting), which has a neutral impact on company sentiment.

Positives

• The transaction represents the vesting of restricted share units, which is a form of executive compensation and indicates the executive is receiving equity as part of their compensation package.

Negatives

• The transaction involves the disposition of shares, albeit for tax purposes, which reduces the executive's direct shareholding by 2,841 shares.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains solely to an individual executive's share transaction.

Industry Context

This filing details a routine executive compensation event common across publicly traded companies, where shares are withheld to cover tax liabilities upon the vesting of equity awards. It does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of restricted stock units is a standard and widely accepted method of managing executive equity compensation across various industries, including the healthcare and pharmaceutical sectors.
• This transaction aligns with typical compensation structures seen in companies comparable to Bausch & Lomb, such as other large medical device or pharmaceutical companies that utilize equity incentives for their executives.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine compensation-related transaction and not a discretionary sale by the executive. It reflects the ongoing vesting of executive equity awards.
• Employees: No direct impact beyond the executive involved.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where shares were withheld to cover tax obligations upon the vesting of restricted share units for an executive. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the investment thesis.

Keywords

Bausch & Lomb, BLCO, Form 4, insider transaction, share withholding, executive compensation, restricted stock units, RSU, tax obligations